Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on the distribution of radioactive drugs in the body to obtain physiological and pathological information [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear medicine imaging equipment, and radiation therapy devices [2] Development Environment - The Chinese government has been actively promoting the nuclear medicine industry through various policies, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - Local governments, such as in Guangdong and Sichuan, have also introduced plans to accelerate the development of the nuclear medicine sector [6][7] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant advancements in technology and capabilities, transitioning from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Nuclear Industry, East China Pharmaceutical, and Yuanda Medical, with East China Pharmaceutical holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new radioactive drug developments, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in diverse nuclear medicine services [20]

Core Insights - Nuclear medicine is a crucial interdisciplinary field that combines nuclear physics, chemistry, biology, and medicine for diagnosis, treatment, and research using radioactive isotopes [1][2][4] - The market for diagnostic and therapeutic radioactive drugs in China has grown from 2.2 billion yuan in 2017 to 5.4 billion yuan in 2023, with projections of 7.1 billion yuan in 2024 and 9.3 billion yuan in 2025 [1][10] - The industry is experiencing a significant transformation from a niche technology to a core diagnostic tool for tumors and chronic diseases, marking the next decade as a golden development period [1][20] Industry Definition - Nuclear medicine involves the application of radioactive isotopes for medical diagnostics, treatment, and research, focusing on imaging and radiotherapy [2][4] - The industry encompasses radioactive drugs, medical radiation sources, nuclear imaging equipment, and radiotherapy devices [2] Development Environment - The Chinese government has implemented various policies to support the nuclear medicine industry, including the "Three-Year Action Plan for High-Quality Development of Nuclear Technology Application Industry (2024-2026)" [6][7] - These policies aim to enhance innovation, expand clinical applications, and create new opportunities for related enterprises [6] Current Market Status - The nuclear medicine market in China is characterized by high market concentration, with a CR1 of 31.16%, CR2 of 50.01%, and CR3 of 53.69% [12] - The industry has seen significant technological advancements, moving from a lagging position to a competitive one [14] Competitive Landscape - Major players in the nuclear medicine market include China Dongfang, East Cheng Pharmaceutical, and Yuanda Medical, with East Cheng holding the largest market share at 35.16% [16][18] - The market is structured into tiers, with several companies classified in the first and second tiers based on their registered capital [16] Future Trends - The nuclear medicine industry in China is poised for substantial growth due to increasing demand for precision medicine, new drug development, and supportive policies [20] - The aging population and rising health management awareness are expected to drive explosive growth in nuclear medicine services [20]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國同輻股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01763 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 79,968,800 | RMB | | | 1 RMB | | 79,968,800 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 79,968,800 | RMB | | | 1 RMB | | 79,968,800 | | 2. 股份分類 | ...

新股活动 中慧生物-B (招股中) 信义光能 天安卓健 信义玻璃 信义能源 协合新能源 电讯盈科 远东宏信 金力永磁 滨海泰达物流 尝高美集团 MS CONCEPT 汇舸环保 麦迪森控股 天平道合 大众金融控股 （派息日） 美亨实业 （派息日） 滔搏 （除净日） 滔搏 （除净日） 中国同辐 （派息日） 美瑞健康国际 （除净日） 大众公用 （派息日） 交运燃气 （派息日） 卡罗特 （派息日） 鲁商服务 （派息日） 中国科培 （除净日） 分红派息 业绩公布日 股东大会召开日 智通财经APP获悉，2025年8月1日，港股上市公司投资日志如下： 类别 公司 ...

Core Viewpoint - China Nuclear High-Tech (01763.HK) announced plans for capital increase through Beijing Property Exchange to address funding needs and optimize capital structure [1] Group 1: Company Financials - As of December 31, 2024, China Nuclear High-Tech's subsidiary, Chengdu Zhongke Gaotong Isotope Co., has a debt-to-asset ratio of 68.41% [1] - The capital increase aims to alleviate financial pressure and support core business expansion and operational capacity enhancement [1] Group 2: Strategic Implications - The board believes that the capital increase will ensure sustainable development for China Nuclear High-Tech and align with overall financial management requirements [1] - This move is expected to enhance the overall asset quality and risk resistance capability of the group [1]

中国同辐(01763)公布，公司非全资附属公司成都中核高通同位素股份有限公司(中核高通)拟透过于北京 产权交易所公开褂牌程序进行增资。 截至2024年12月31日，中核高通资产负债率为68.41%，为解决发展资金需求及优化其资本结构，中核 高通拟透过潜在增资事项缓解其资金压力，支持其核心业务拓展及运营能力提升。董事会认为，此次增 资既能保障中核高通的可持续发展，亦符合集团整体财务管控要求，有利于增强集团整体资产品质和抗 风险能力。 ...

截至2024年12月31日，中核高通资产负债率为68.41%，为解决发展资金需求及优化其资本结构，中核 高通拟透过潜在增资事项缓解其资金压力，支持其核心业务拓展及运营能力提升。董事会认为，此次增 资既能保障中核高通的可持续发展，亦符合集团整体财务管控要求，有利于增强集团整体资产品质和抗 风险能力。 智通财经APP讯，中国同辐(01763)公布，公司非全资附属公司成都中核高通同位素股份有限公司(中核 高通)拟透过于北京产权交易所公开褂牌程序进行增资。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 內幕消息 中核高通透過公開掛牌方式進行潛在增資事項 潛在增資事項的對價將基於一名有信譽的估值師對中核高通進行的評估值釐定。 進行潛在增資事項的理由及裨益 截至2024年12月31日，中核高通資產負債率為68.41%，為解決發展資金需求及優 化其資本結構，中核高通擬透過潛在增資事項緩解其資金壓力，支持其核心業務 拓展及運營能力提升。董事會認為，此次增資既能保障中核高通的可持續發展， 亦符合本集團整體財務管控要求，有利於增強本集團整體資產品質和抗風險能力。 1 有關中核高通的資料 中核高通為本公司的非全資附屬公司，主要從事放射性同位素產品的開發、生產 和銷售，兼營進出口貿易、貨物運輸。截至本公告日期，本公司、四川青衣開發 投資集團有限公司、瑪西 ...

香港联交所最新资料显示，7月24日，瑞银增持中国同辐(01763)3.42万股，每股作价15.9819港元，总金 额约为54.66万港元。增持后最新持股数目约为403.05万股，最新持股比例为5.04%。 ...

智通财经APP获悉，香港联交所最新资料显示，7月24日，瑞银增持中国同辐(01763)3.42万股，每股作 价15.9819港元，总金额约为54.66万港元。增持后最新持股数目约为403.05万股，最新持股比例为 5.04%。 ...